Ovid Therapeutics' OV329: Promising Safety and Efficacy Lead to Buy Rating

TipRanksDec 10, 2024 20:05 · Ratings

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Ovid Therapeutics (OVID)

TipRanksDec 9, 2024 21:20 · Ratings

H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $3

Futu NewsDec 6, 2024 00:35 · Ratings

Ovid Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow JonesDec 4, 2024 19:59 · Ratings

Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4

Futu NewsNov 14, 2024 22:33 · Ratings

Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating

Futu NewsNov 14, 2024 21:31 · Ratings